More than 40 years after the initial report1 of a beneficialeffect of aminopterin, the parent compound of methotrexate,in rheumatoid arthritis and psoriasis, there is a resurgenceof interest in the use of methotrexate in autoimmune and inflammatorydiseases. In this issue of the Journal, Feagan and colleaguesreport that in a 16-week double-blind trial, intramuscular methotrexate(25 mg once weekly) was more effective than placebo in improvingsymptoms and reducing requirements for prednisone in patientswith chronically active Crohn's disease.2 A greater proportionof patients were in clinical remission in the methotrexate group(39.4 percent) than in the . . . [Full Text of this Article]
Curreli, F., Cerimele, F., Muralidhar, S., Rosenthal, L. J., Cesarman, E., Friedman-Kien, A. E., Flore, O.
(2002). Transcriptional Downregulation of ORF50/Rta by Methotrexate Inhibits the Switch of Kaposi's Sarcoma-Associated Herpesvirus/Human Herpesvirus 8 from Latency to Lytic Replication. J. Virol.
76: 5208-5219
[Abstract][Full Text]
Lloyd, M.E., Carr, M., Mcelhatton, P., Hall, G.M., Hughes, R.A.
(1999). The effects of methotrexate on pregnancy, fertility and lactation. QJM
92: 551-563
[Full Text]
Hanauer, S. B.
(1996). Inflammatory Bowel Disease. NEJM
334: 841-848
[Full Text]
Mitchell, A. A., Van Bennekom, C. M., Louik, C.
(1995). A Pregnancy-Prevention Program in Women of Childbearing Age Receiving Isotretinoin. NEJM
333: 101-106
[Abstract][Full Text]
Fogari, R. A., Hoch, S., Zonneveld, I.M., Bos, J.D., Weinblatt, M. E.
(1995). Methotrexate for Chronic Diseases in Adults. NEJM
332: 1791-1792
[Full Text]